# Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

Study · id `cardio:ct-nct02251067` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02251067](<https://clinicaltrials.gov/study/NCT02251067>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02251067

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

## Technical summary

Registry record NCT02251067. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2017-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 165 participants (enrolled count; ClinicalTrials.gov record NCT02251067, source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02251067, source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)
- Primary completion: 2017-03 (actual) (ClinicalTrials.gov record NCT02251067, source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)
- Completion: 2017-03 (actual) (ClinicalTrials.gov record NCT02251067, source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02251067, source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02251067-2017-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
- Condition: Diabetic Nephropathy
- Intervention (Drug): VPI-2690B low dose
- Intervention (Drug): VPI-2690B medium dose
- Intervention (Drug): Placebo to match VPI-2690B
- Intervention (Drug): VPI-2690B high dose
- Lead sponsor: Vascular Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 7ebb4a205ea6a355609ef1c6a21551c987d7b895cb2d02656bd6f1b9433d8443
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
